Mode
Text Size
Log in / Sign up

Anemia prevalence is 56.4% in heart failure patients, linked to worse clinical profilesLow Iron Could Be Making Heart Failure Worse

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider anemia assessment in HF patients, but note associations are observational and not causal.

This retrospective cohort study analyzed 2,144 adult patients with heart failure (HF) from National Guard Health Affairs hospitals in Saudi Arabia. It examined anemia status and severity (categorized as mild, moderate, or severe based on hemoglobin levels) compared to non-anemic patients, with primary outcomes including prevalence and severity of anemia and the association between hemoglobin levels and B-type natriuretic peptide (BNP). Secondary outcomes covered independent predictors of anemia, clinical characteristics, laboratory parameters, and outcomes such as cardiovascular mortality, though follow-up duration was not reported.

Main results showed anemia prevalence was 56.4% (95% CI 54.3% to 58.5%), with moderate anemia most common at 53.2% of anemic cases. Increasing anemia severity was associated with older age, longer HF duration, higher prevalence of chronic kidney disease (CKD) and atrial fibrillation, worsening renal function, hypoalbuminemia, and progressively higher BNP and troponin levels, with all associations statistically significant (p < 0.05). However, absolute numbers and effect sizes for these associations were not reported, and outcomes like cardiovascular mortality lacked specific data.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported. Key limitations include that contemporary real-world data describing the burden and relationship with biomarkers of HF severity remain limited, and the study design is observational, preventing causal inferences. Funding or conflicts of interest were not reported. In practice, these findings support routine anemia assessment in comprehensive HF care due to its high prevalence and links to disease severity, but clinicians should interpret the associations cautiously, as they do not confirm causation or directly address clinical outcomes.

Heart failure does not mean the heart has stopped. It means the heart is not pumping as strongly as it should.

It affects tens of millions of people worldwide. Symptoms include fatigue, swelling in the legs, and shortness of breath, even when resting.

Doctors already have good medicines for heart failure. But patients often still feel tired and weak, even when their heart numbers look better.

That gap between "treated" and "feeling well" is frustrating. This study points to one reason why.

The quiet second problem

Red blood cells carry oxygen. When a person has anemia, their blood carries less oxygen to the muscles — including the heart muscle itself.

For years, anemia in heart failure has been treated as a side note. Something to fix later, if at all.

But here's the twist. This new research suggests anemia is not a side note. It may be a warning light on the dashboard — one that lights up brighter as the heart gets sicker.

How the body connects the two

Think of the heart as a water pump and the blood as the delivery truck.

A weak pump already struggles to push fluid through the pipes. Now imagine the trucks are also half-empty. The whole system slows down, and every organ feels it.

The kidneys are especially affected. They make a hormone that tells the body to produce red blood cells. When kidneys suffer — which is common in heart failure — that signal weakens. Fewer red blood cells get made. Anemia sets in. The heart works harder. The cycle repeats.

Inside the study

Researchers looked back at the records of 2,144 adult heart failure patients treated at National Guard Health Affairs hospitals in Saudi Arabia.

The median age was 67. About half were women. The team sorted patients by anemia severity — mild, moderate, or severe — and compared their health profiles.

They also looked at BNP, a blood marker that rises when the heart is under stress.

Anemia was present in 56.4% of patients. That is more than one in two.

Moderate anemia was the most common form, showing up in just over half of those affected. Severe anemia was rarer but carried the worst outlook.

As anemia got worse, so did nearly everything else. Patients were older. They had been living with heart failure longer. They were more likely to have chronic kidney disease (long-term kidney damage) and atrial fibrillation (an irregular heartbeat).

Their kidney function was lower. Their albumin — a protein that reflects nutrition and health — was lower too. And their BNP levels were higher, meaning their hearts were under more strain.

This doesn't mean anemia causes heart failure to worsen, only that the two move together closely.

The bigger picture

This study does not stand alone. Earlier research in Europe and North America has shown similar patterns.

What makes this one useful is its size and its setting. It is one of the largest real-world looks at anemia in heart failure from the Middle East, and it confirms that the link holds across different populations and health systems.

For doctors, the message is simple. A basic blood test can flag a problem that may be dragging a patient down — and one that can often be treated.

If you or a loved one has heart failure, ask your doctor about your hemoglobin level at your next visit. It is a routine blood test.

Do not start iron supplements or other treatments on your own. Too much iron can be harmful. The cause of anemia matters — it could be low iron, kidney-related, or something else entirely.

The goal here is awareness, not self-treatment. Bring it up. Ask the question.

Limitations to keep in mind

This was a retrospective study. That means the researchers looked at existing medical records rather than following patients forward in time.

That approach is useful, but it cannot prove cause and effect. It also came from hospitals in one country, so the exact numbers may differ elsewhere.

And because the study relied on recorded data, some details — like why each patient had anemia — were not always clear.

The next step is testing whether treating anemia actually helps people with heart failure feel better and live longer.

Some trials are already doing this, especially with intravenous iron. Early results are promising but not yet definitive.

For now, this study strengthens the case for making anemia checks a standard part of heart failure care — not an afterthought. Good medicine often starts with simply looking harder at what we already have in front of us.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Anemia is a common comorbidity in heart failure (HF) and is associated with adverse outcomes, yet contemporary real-world data describing its burden and relationship with biomarkers of HF severity remain limited. To evaluate the prevalence and severity of anemia in patients with HF, identify independent predictors, and examine the association between hemoglobin levels and B-type natriuretic peptide (BNP). We conducted a multicenter retrospective cohort study of adult patients with HF across National Guard Health Affairs hospitals in Saudi Arabia. Anemia was categorized as mild, moderate, or severe based on hemoglobin levels. Clinical characteristics, laboratory parameters, and outcomes were compared by anemia status and severity. Multivariable logistic regression identified independent predictors of anemia. Correlation and linear regression analyses assessed the relationship between hemoglobin and BNP, adjusting for age, sex, chronic kidney disease (CKD), and estimated glomerular filtration rate (eGFR). Among 2,144 patients (median age 67 years; 50.8% female), anemia was present in 56.4% (95% CI 54.3%–58.5%), with moderate anemia most common (53.2%). Increasing anemia severity was associated with older age, longer HF duration, higher prevalence of CKD and atrial fibrillation, worsening renal function, hypoalbuminemia, and progressively higher BNP and troponin levels (all p  Anemia is highly prevalent in HF and closely linked to disease severity, adverse clinical profiles, and increased cardiovascular mortality, supporting routine anemia assessment in comprehensive HF care.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.